KalVista Pharmaceuticals: Has Potential But With Caveats
Source: SeekingAlpha
2026-03-12 11:07:25 ET
Shares of protease inhibitor concern KalVista Pharmaceuticals, Inc. ( KALV ) have moved up following FDA approval of its HAE therapy Ekterly. Since the July 2025 green light, the first oral on-demand treatment for HAE attacks has generated revenue of $49 million, already receiving patient start forms from ~20% of U.S. patient population. With likely one year plus of blue sky before an oral competitor from Pharvaris ( PHVS ) and a single-administration functional cure from Intellia ( NTLA ) hit the market, KalVista merited another look. An analysis/recommendation follows below....
Read the full article on Seeking Alpha
For further details see:
KalVista Pharmaceuticals: Has Potential But With Caveats
Pharvaris N.V.
NASDAQ: PHVS
PHVS Trading
1.78% G/L:
$26.28 Last:
28,342 Volume:
$25.65 Open:
PHVS Latest News
March 20, 2026 06:50:00 am
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 11, 2026 06:50:00 am
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
PHVS Stock Data
$1,492,567,159
37,790,994
N/A
37
N/A
Biotechnology & Life Sciences
Healthcare
NL
Leiden
